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Abstract
The purpose of this chapter is to clarify the prevalence of Helicobacter pylori infection (HPI)
and atrophic corpus gastritis (ACG) in patients with intellectual disability (ID) and review
the literature surrounding them. We measured the levels of pepsinogen I, pepsinogen II,
gastrin-17b (basal), and Helicobacter pylori antibodies from 243 patients with intellectual
disability living in Rinnekoti Research Centre at Lakisto area during 2009–2011. We
determined the levels of hemoglobin, mean cell volume (MCV), hematocrit, and the mean
amount (MCH) and concentration (MCHC) of red cell hemoglobin, the counts of erythro-
cytes, leucocytes, and thrombocytes. About 43% had high level of Helicobacter pylori
antibodies and 6% ACG. Our results show that Helicobacter pylori infection occurs
approximately twice the rate it appears in the normal population. Also, the incidence of
ACG was higher among patients with ID than normal population. ID may be a risk of
getting the Helicobacter pylori infection (HPI) and ACG. In addition, it was found that the
level of thrombocytes was increased in HPI group compared to normal group and
decreased in ACG group compared to normal group. This study shows that there is
clearly a need to investigate (test) more stomach condition in patients with ID.
Keywords: helicobacter, Helicobacter pylori, pepsinogen, gastritis, atrophic corpus gastritis,
intellectual disability, personalized medicine
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1. Literature review
1.1. Helicobacter pylori infection
Helicobacter pylori is a common Gram-negative bacterium, which may colonize the human
stomach, wherein it can induce various gastroduodenal disorders (chronic gastritis, ulceration,
atrophic corpus gastritis, and gastric cancer). However, only a small part of the people, who
are colonized, develops associated diseases. It is estimated that H. pylori infection (HPI) affects
more than half of the adult population worldwide [1] and is responsible for 75% of all gastric
cancer cases [2]. In Finland and many other countries, the prevalence of H. pylori is decreased
in last decades, in Finland to the level of approximately 15% of population [3]. Intellectually
disabled children are a vulnerable subgroup and may experience higher rates of infections and
morbidities [4]. H. pylori infection and gastric cancer occur at higher rates in subjects with ID
than in the general population [5]. In institutionalized patients with intellectual disability (ID),
Helicobacter pylori infection (HPI) occurs twice the rate it appears in the normal population [6–8].
It is suggested that the transmission of HPI occur via an oral-oral or fecal-oral pathway. Ohwada
et al. [9] concluded that a high frequency of mild norm chromic anemia in institutionalized
people with ID was observed. According to them, medications and chronic inflammation may
increase the risk of anemia. Telaranta-Keerie et al. [10] noted the prevalence of 3.5 % of popula-
tion for atrophic corpus gastritis (ACG) and also found that ACG may cause impairment in
secretion of intrinsic factor, resulting in vitamin B12 deficiency. Because of these observations, we
decided to evaluate the hematological values of our patients with ID. ACG can be autoimmune
in origin or it can appear as multifocal atrophic gastritis (MAG) [11, 12]. According to Telaranta-
Keerie et al. [10], MAG is always HPI-initiated. Achlorhydric or hypochlorhydric stomach with
ACG may result in malabsorption of vitamin B12, micronutrients, and medicines [13]. It is well
known that the stomach must be acid in order to absorb B12. Many people already suffer from
borderline B12 deficiency—this is a difficult vitamin for the body to assimilate, but essential for
normal biochemistry. Therefore, achlorhydria may be associated with vitamin B12 deficiency in
the setting of pernicious anemia. Parenteral vitamin B12 may be important in selected patients.
Achlorhydria is associated with thiamine deficiency in the setting of bacterial overgrowth
[14–16]. In addition, increasing evidence accumulates that H. pylori infection may interfere with
many biological processes and have a role in birth of several other extra-gastroduodenal mani-
festations including among others iron deficiency anemia, immune thrombocytopenic purpura,
metabolic syndrome and diabetes mellitus, nonalcoholic fatty liver disease, coronary artery
disease and cerebrovascular disorders [17]. Because of these facts, ACG is important disease to
be diagnosed and recognized [18, 19]. It has been observed that Helicobacter pylori infection can
cause rumination and numerous other behavioral disorders [20].Helicobacter pylori are associated
with gastric atrophy and gastric carcinoma [21].
1.2. The role of epidemiology in understanding the health effects of Helicobacter pylori in
intellectual disability
H. pylori infection appears to be almost universal among certain groups of people with intel-
lectual disability and appears to be a relatively silent condition in this population, even in
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those with more virulent strains [22]. The ID is potentially at risk of significant but preventable
morbidity and mortality from the disease consequences of this infection [23]. The efficacy of
standard treatment protocols appear lower than that in the general population, and in some,
the side effects are more prominent [24]. The diagnosis of H. pylori infection can be made with
reasonable clinical certainty using the fecal antigen test (and serology under some conditions)
or, in those with greater abilities, using the urea breath test [25]. Although eradication of
infection does not change the level of maladaptive behavior or intellectual disability, it may
reduce the risk of the disease consequences of H. pylori. Given the clinical silence of the
infection, the virulence of the strains, the acceptability of the diagnostic tests, and knowledge
of the risk factors for infection, despite a possible lower eradication rate and higher rate of side
effects, a strong argument can be made to proactively screen for and treat H. pylori infection
among groups of people with intellectual disability who have a history of institutionalization,
greater levels of intellectual disability or maladaptive behavior, or live with flatmates with
hypersalivation or fecal incontinence [5].
Intellectually disabled children are a vulnerable subgroup and may experience higher rates of
infections and morbidities [4]. H. pylori infection and gastric cancer occur at higher rates in
subjects with ID than in the general population [5, 7]. Many children with ID and neurological
impairments are not able to co-operate with performance of noninvasive test such as UBT [7].
In addition, because of limitations in their intellectual and adaptive functioning, such children
are unable to report their symptoms. Behavior of people with ID is often difficult to explain
and reactions may be similar on physical and emotional stress that is why they may be
misunderstood and over medicated. One of the main reasons to begin this research study in
our research center—Rinnekoti Research Centre—was the fact that patients with ID very often
have difficulties to recognize, localize and indicate their symptoms. Although life-long
H. pylori associated morbidities are well known, relatively few studies have addressed the
status of H. pylori infection in people with ID [5].
1.3. Helicobacter infection and gastric neoplasia
As discussed above, Helicobacter pylori are one of the world’s most common pathogens with a
colonization of about 60% of the general population [26, 27]. It is estimated that H. pylori
infection affects more than half of the adult population worldwide [1] and is responsible for
75% of all gastric cancer cases [2]. No mode of transmission is fully known, however, many
factors may contribute such as socio-economic and poor living standards, poor nutrition and
physical activity, and possibly poor access to health services. However, most individuals never
develop clinical disease [28].
Gastrointestinal problems in handicapped children with neurodevelopmental disabilities are
chronic and present long-term management problems. These conditions include dysphagia
(60%), chronic pulmonary aspiration (41%), gastroesophageal reflux (32%), abdominal pain and
gastritis (32%), constipation (74%), and malnutrition (33%) [29]. Growth failure and malnutrition
are common in children with cerebral palsy, particularly in those with spastic quadriplegia, of
which 85% report feeding problems [30, 31]. In addition, 20–30% of hemiplegic and diplegic
cerebral palsy children are underweight for age [26, 32]. There are multifactorial causes:
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insufficient food intake, feeding problems, increased nutrient losses from vomiting or
diarrhea, and alterations in energy requirements in epileptic or metabolic syndromes where
increased muscle tone or involuntary movements are seen. What is now clear is that undernu-
trition in cerebral palsy is often correctable and that providing a balanced diet and better
nutrition can result in improvement in long-term spasticity, appearance, and effect of these
children [33].
Good number of studies have been published in persons with intellectual disability, however,
large-scale scientific studies have not been publishedwith a population case-control study [22, 32,
34]. Harris et al. [35] (10) reported that hospital residents under 40 years of age had a 87%
prevalence of HP compared with 24% for controls, whereas the overall prevalence for all ages
was 87% for residents, and 43% for controls in hospital residents with severe learning disabilities.
A larger study including 338 intellectually disabled and 254 controls from Holland (12) found a
prevalence of 5% in children and 50% in the elderly in the general population, whereas 83% of the
disabled and 27% of the healthy employees were infected. The presence of HP was significantly
associated with male gender, longer duration of institutionalization, an IQ below 50, rumination,
and a history of upper abdominal symptoms. Another study was conducted to determine the
occurrence of HP infection in persons, who presented with severe dyspeptic symptoms and to
monitor clinically the effect of treatment [36]. Over a 1-year period, a total of 43 persons (total
population in care was 224) had severe dyspeptic symptoms and 42 persons (98%, 26 males, 16
females, mean age 45 years, mean institutionalization 20 years) had HP.
1.4. Treatment regimens used for H. pylori eradication
H. pylori infection is most likely acquired by ingesting contaminated food and water, and
through person to person contact. H. pylori infections are usually treated with antibiotics to
help prevent the bacteria from developing a resistance to any particular antibiotic. Helicobacter
pylori infection causes progressive damage to gastric mucosa and results in serious disease
such as peptic ulcer disease, MALT lymphoma, or gastric adenocarcinoma in 20–30% of
patients [37]. Most persons who are infected with H. pylori never suffer any symptoms related
to the infection; however, H. pylori causes chronic active, chronic persistent, and atrophic
gastritis in adults and children. Infection withH. pylori also causes duodenal and gastric ulcers.
Infected persons have a two- to six-fold increased risk of developing gastric cancer and
mucosal-associated-lymphoid-type (MALT) lymphoma compared with their uninfected coun-
terparts. The role of H. pylori in nonulcer dyspepsia remains unclear [38]. Therapy for H. pylori
infection consists of 10 days to 2 weeks of one or two effective antibiotics, such as amoxicillin,
tetracycline (not to be used for children <12 years), metronidazole, or clarithromycin, plus
either ranitidine bismuth citrate, bismuth subsalicylate, or a proton pump inhibitor [39, 40]. H
pylori eradication rates were higher for a 7-day antibiotic regimen containing lansoprazole,
amoxicillin, and clarithromycin (LAC), when used as first-line therapy compared with
levofloxacin, amoxicillin, and lansoprazole (LAL) [39]. Yoon et al. [40] investigated the efficacy
of a moxifloxacin-containing triple therapy as second-line therapy forH. pylori infection as well
as the effect of treatment duration and antibiotic resistance on the eradication rate [40].
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Combination drug therapy regimens commonly used to treat H. pylori infection includes a
proton pump inhibitor (PPI) plus clarithromycin plus amoxicillin or metronidazole and a
proton pump inhibitor plus a bismuth compound plus metronidazole plus tetracycline. How-
ever, all medicines have side effects. But many people don’t feel the side effects or they are able
to deal with them [38, 41, 42].
1.5. Helicobacter pylori infection and oxidative stress
Oxidative stress results from the damaging action of reactive oxygen species. These molecules
react with proteins, lipids, or DNA, altering their structure and causing oxidative damage to the
cells. Reactive oxygen species (ROS) are produced during normal and physiological process,
which inevitably leads to the generation of oxidative molecules: superoxide (O2•
_), hydrogen
peroxide (H2O2), or hydroxyl radical (•OH). Oxidative stress is implicated in a large number of
diseases: cancer (oxidative damage to DNA causes mutations that can lead to carcinogenesis),
atherosclerosis (atherosclerotic plaques are made from oxidized fat), and neurodegenerative
diseases (oxidative damage is a central component of nerve cell destruction). Indicators of oxida-
tive stress have been detected inmuscles and blood of IDpatients. Oxidative damage can alter the
blood-brain barrier, which could explain some of the cognitive problems experienced by patients.
There is an increasing evidence that microbial pathogens induce oxidative stress in infected
host cells [43–45] and this may represent an important mechanism leading to epithelial injury
in H. pylori infection [46].
Oxidative stress could well play a role in the altered epithelial proliferation, increased apopto-
sis, and increased oxidative DNA damage [47–49] associated with H. pylori infection.
Evidence for this includes increased levels of reactive oxygen species (ROS) measured in the
mucosae of infected patients [48, 50, 51]. While activated, ROS-releasing phagocytic leukocytes
recruited to the gastric mucosa during infection represent one obvious source of oxidative
stress [43, 50].
The mechanism of tissue damage and cell proliferation in H. Pylori infection remains unknown,
although cytokines, chemokines, growth factors, including nitric oxide synthase and potent
neutrophil. Derive reactive oxygen metabolism have all been proposed to contribute to such
damage [52–54]. HP infection is associated with the increased production of free radicals in the
gastric mucosa [50]. Accumulated free radicals in the tissue initiate lipid peroxidation of cell
membranes and threaten cell integrity. Antioxidant may be useful in HP-related mucosal disease
[47]. Evidence suggests that microbial pathogens induce oxidative stress in infected host cells
[43–45], which represents an important mechanism causing damage to the epithelial in H. pylori
infection [55]. Helicobacter pylori is the major cause of acute and chronic gastritis, gastric, and
duodenal ulcer and increased incidence of gastric adenocarcinoma and elevated gastric mucosa
lymph proliferation. Reactive oxygen species have been suggested as one of the main causes of
cell injury in H. pylori associated gastritis. H. pylori mutants that are defective in RuvC have
increased sensitivity to DNA-damaging agents and to oxidative stress, exhibit reduced survival
within macrophages, and are unable to establish successful infection in a mouse model [56].




2.1. Material and methods
GastroPanel test (Biohit Oyj, Helsinki) was used. The test consisted of measurement of plasma
pepsinogen I, pepsinogen II (PG I, PG II and PG I/PG II ratio), H. pylori IgG antibodies (HpAb)
and gastrin-17-basal by the ELISA method. Test results, together with a short interpretation of
the results are created by the GastroSoft software. The GastroSoft software uses an algorithm
that is based on the levels of PG I, PG II, HpAb, and gastrin-17-basal in plasma as measured by
GastroPanel. When the results showed a low PG I level (<30 μg/l) and/or a low PG I/PG II ratio
(<3), the GastroSoft interpretation was “moderate or severe atrophic corpus gastritis”. Cases
fulfilling these criteria were considered to have advanced ACG. If PG I level and PG I/PG II
ratio were normal but the patient had an elevated HpAb result (≥30 EIU), this was interpreted
as “nonatrophic H. pylori gastritis”. When the levels of all the biomarkers were within their
reference ranges (PG I ≥ 30 μg/l and PG I/PG II ratio ≥ 3, HpAb below 30 EIU), the GastroSoft
interpretation was “healthy, normal stomach mucosa”.
2.2. Laboratory determinations and reagents
Vacuette serum tubes were used to obtain serum samples and vacuette K2EDTA tubes were
used to obtain hematological samples. Hemoglobin, mean cell volume (MCV), hematocrit,
erythrocytes, thrombocytes, and leukocytes were assayed with Sysmex KX-21 N analyzer. All
used reagents were reagent grade. All laboratory determinations were controlled with the
control samples from Labquality Ltd., Helsinki, Finland. All enzyme immunoassays were
done with BP 800 reader.
2.3. Study population
The study material consisted of blood samples from patients with intellectual disability (243
individuals). Patients with ID lived in groups containing 6–8 persons during 2009–2011. Age
was from 10 to 80. The whole group consisted 157 male and 86 female patients with ID.
Sanitary facilities were common for each group as normal family living. The personnel taking
care of these patients was living with them for 24 hours per day with 8–10 hours shifts.
3. Results
We measured the levels of pepsinogen I, pepsinogen II, gastrin 17-beta, and Helicobacter pylori
antibodies from 243 patients with intellectual disability (157 male patients and 86 female
patients). Results are shown in Tables 1 and 2 and Figures 1–4. The prevalence of subjects
with ACG, HPI, and normal stomach mucosa is shown in Table 1. Among male patients, 7%
had ACG, while among female patients, 4.7% had ACG. 6.2% of all patients had ACG. Among
male patients, 45.2% had HPI, while among female patients, 39.5% had HPI. About 43.2% of all
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patients had HPI. Among male patients, 47.8% had normal stomach mucosa, while among
female patients, 55.8% had normal stomach mucosa. About 50.6% of all patients had normal
stomach mucosa (Table 1). Differences in the levels of pepsinogen II, PG I/PG II, and
Helicobacter pylori antibodies between HPI group and normal group were statistically
extremely significant. Differences in the levels of pepsinogen I, PG I/PG II, and Helicobacter
pylori antibodies between ACG group and normal group were also statistically extremely
significant. Differences in the levels of hemoglobin, hematocrit, erythrocytes, and leucocytes
between HPI group and normal group were not statistically significant. The level of thrombo-
cytes was increased in HPI group compared to normal group and decreased in ACG group
compared to normal group. These differences were statistically significant. Differences in the
MCHC, MCH, and MCV were not statistically significant between these groups. Same results
were between ACG group and normal group (Table 2).
Table 2. Five gastro and eight hematological parameters in groups with advanced corpus gastritis (ACG), Helicobacter
pylori antibodies (HPI), and healthy stomach mucosa (normal).
Table 1. Prevalence of subjects with advanced atrophic corpus gastritis (ACG), elevated Helicobacter pylori antibodies,
and normal stomach mucosa in male and female patients with ID.
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Figure 2. The levels of pepsinogen II on 243 patients with ID.
Figure 1. The levels of pepsinogen I on 243 patients with ID.
Personalized Medicine, in Relation to Redox State, Diet and Lifestyle8
Figure 4. The levels of H. pylori antibodies on 243 patients with ID.
Figure 3. The levels of Gastrin 17-b on 243 patients with ID.




This study provides an overview of the best available evidence on the prevalence of H. pylori
infection obtained from patients with intellectual disability.
The level of ID and environmental factors may be related to the risk of infection with H. pylori [7].
According to Merrick, 43 persons (total population in care was 224) had severe dyspeptic symp-
toms.Wallace et al. [7] showed that adultswith IDmaybe at risk of infectionwithHPI.According to
their results, a long period of institutionalization living with other patients predisposes to HPI.
Helicobacter pylori among patients with ID living in hospitals are common [7]. In institutionalized
patients with intellectual disability (ID), Helicobacter pylori infection (HPI) occur twice the rate it
appears in the normal population [6–8]. However, this trend has not been before observed in
Finland. The patients with ID lived in groups containing 6–8 persons. Sanitary facilities were
common for each group as normal family living. It is suggested that the transmission of HPI occur
via anoral-oral or fecal-oral pathway. Themechanismof transmissionof this pathogen is not known
exactly. But it is known that the rate of this disease is increasedwith age and other living conditions.
According to our findings, patients with ID and age of 50 and living for a long time in group
residences are high at risk to get Helicobacter pylori infection and also so atrophic corpus gastritis.
Becausewell-beingof patientswith ID is important,wedecided todetermine also the hematological
values of these people. We did not find any big differences between the patients with healthy and
sick stomach mucosa. The count of thrombocytes was increased in HPI group and decreased in
ACG group. Thrombocytes have an important role in inflammation [57]. They participate in
inflammatory response to H. pylori infection by activation and aggregation as well as acting as a
source of inflammatory mediators and modulating the activity of other inflammatory cells in
stomach mucosa [58]. The volume of thrombocytes may be increased during infection. Their
persistent activation and enhanced destruction production process during infection may lead to
decreased amounts of them [59]. However, it seems that there lacks association between H. pylori
infection and various markers of systemic inflammation including thrombocyte/lymphocyte ratio
in adults with chronic asymptomatic H. pylori infection [60]. Helicobacter pylori infection and its
consequences may be severe to people with ID. Wallace et al. [7] concluded that if this infection
leads to increased levels of maladaptive behavior, this could result in loss of social opportunities,
sedativedruguse and sodecrease ofwell-being. Themental pressure amongworkers in institutions
for people with ID will increase. Böhmer et al. [61] and Schryver et al. [62] found that Helicobacter
pylori infection is an occupational risk in healthcareworkersworking in institutions for peoplewith
ID. This observation gives the reason to also investigate all workers taking care of patients with ID.
Proujansky et al. [20] stated that rumination may be a possible symptom of Helicobacter pylori
infection. Rumination occurs more frequently in patients with ID. Dentists play the important
role in finding patients with rumination. From these patients, it is important to investigate
Helicobacter pylori infection and treat it. Ohwada et al. [9] found that the prevalence of anemia
was increased on patients with ID. According to their results, most patients showed a
normocytic norm chromic anemia pattern. They say that medications and inflammation may
increase the risk of anemia. We did not find differences on hemoglobin levels between the
patients with normal and sick mucosa of stomach. We need more research on this field.
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Wallace et al. [63, 64] reported that 7% of institutionalized adults with ID treated for
Helicobacter pylori infection and test negative at the end of treatment are at risk of reinfection.
They suggest that patients with ID should retest at an interval of approximately 3–5 years after
apparent eradication. More research is needed to evaluate the effects of Helicobacter pylori
infection on pain and use of drugs on patients with ID. Taking care of this infection, we can
probably increase the level of well-being of these patients and so to decrease the physical and
physiological pressure of workers in institutions for people with ID. Many studies have
explored the association of H. pylori with hypermethylation of specific genes [65, 66] as well
as hypomethylation of genes [67, 68]. Further research is required to elucidate the exact
mechanisms of inflammation and tumor suppression, which might provide new opportunities
for personalized treatment options.
The poor prognosis of patients with a negative H. pylori status might be the result of a more
aggressive form of gastric cancer [69, 70]. The present study demonstrates that H. pylori positiv-
ity is a beneficial prognostic indicator in patients with intellectual disability, independent of
other clinic pathologic variables. In clinical practice, patients with curatively resected gastric
cancer who are negative for H. pylori may need more careful follow-up and more aggressive
antitumor treatment to prolong life expectancy. Further research is required to elucidate the
exact mechanisms of inflammation and tumor suppression, which might provide new opportu-
nities for personalized treatment options. We believe that the current prospective study is the
first to confirm H. pylori status as a favorable prognostic factor in a large number of intellectual
disability patients with Helicobacter pylori infection and atrophic corpus gastritis in Finland, thus
validating the effect of H. pylori infection status on survival in intellectual disability patients.
Antibiotic susceptibility should be checked in all patients, ideally, before the start of eradication
treatment. The knowledge of local antibiotic resistance and consumption pattern is important in
selecting a reliable regimen [71–73]. Future development forH.pylori therapy shouldbedirected to
overcome individualized antibiotic resistance.Warneke et al. [74] investigated various phenotypic
and genotypic biomarkers of gastric cancer (GC) and concluded whether these biomarkers are
suitable for the identification of GC subtypes, are they of prognostic significance, and should any
of these biomarkers be considered to tailor patient treatment in the future. There remains a need to
better understand theprognostic factors affecting the cure rate ofHelicobacter pylori infectionmight
lead to the development of novel prevention strategies and therapeutic targets. Therefore, person-
alizedmedical approachwill likely increase the cure rate ofH. pylori infection [75].
A complete history could also do away with the need for additional testing and increased
medical expenses for the patient and the healthcare system as a whole.
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